According to a new report from Intel Market Research, the global Empagliflozin Drug market was valued at USD 17,800 million in 2024 and is projected to reach USD 50,340 million by 2032, growing at a robust CAGR of 17.0% during the forecast period (2025-2032). This remarkable growth trajectory is fueled by rising diabetes prevalence globally, increased adoption of SGLT2 inhibitors for...